Kejing Tang Selected Research

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

3/2022	Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
1/2021	Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
1/2019	RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4-mediated transactivation of P57.
1/2018	Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
5/2014	N-Cadherin and Tie2 positive CD34⁺CD38⁻CD123⁺ leukemic stem cell populations can develop acute myeloid leukemia more effectively in NOD/SCID mice.
8/2012	Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
9/2009	Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kejing Tang Research Topics

Disease

22	Neoplasms (Cancer) 04/2024 - 07/2009
17	Leukemia 12/2022 - 09/2009
8	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2023 - 08/2012
7	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2019
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2022 - 09/2009
6	Adenocarcinoma of Lung 03/2024 - 01/2019
3	Neoplasm Metastasis (Metastasis) 12/2023 - 01/2020
3	Lung Neoplasms (Lung Cancer) 10/2023 - 02/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2023 - 01/2019
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 01/2019
2	Inflammation (Inflammations) 01/2019 - 01/2010
1	Lupus Nephritis 05/2024
1	Nausea 01/2024
1	Stomatitis 01/2024
1	Proteinuria 01/2024
1	Hypertension (High Blood Pressure) 01/2024
1	Disease Progression 12/2023
1	B-Cell Lymphoma (Lymphoma, B Cell) 10/2023
1	Infections 01/2023
1	Lymphoma (Lymphomas) 01/2023
1	Anemia 01/2023
1	Postoperative Nausea and Vomiting (PONV) 01/2023
1	Diabetes Mellitus 01/2023
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023
1	Pain (Aches) 01/2023
1	Myositis (Idiopathic Inflammatory Myopathies) 10/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2022
1	Residual Neoplasm 03/2022
1	COVID-19 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Hypoxia (Hypoxemia) 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2020
1	Hematologic Neoplasms (Hematological Malignancy) 01/2020
1	Carcinogenesis 01/2020
1	Cognitive Dysfunction 01/2020
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019
1	B-Cell Leukemia (Leukemia, B Cell) 01/2019

Drug/Important Bio-Agent (IBA)

14	Chimeric Antigen ReceptorsIBA 04/2024 - 03/2016
5	CytokinesIBA 11/2023 - 01/2019
4	osimertinibIBA 04/2024 - 01/2019
4	Tyrosine Kinase InhibitorsIBA 12/2023 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2015
3	Biomarkers (Surrogate Marker)IBA 10/2023 - 01/2019
3	AntigensIBA 01/2023 - 03/2016
2	ErbB Receptors (EGF Receptor)IBA 01/2024 - 08/2021
2	AntibodiesIBA 07/2023 - 01/2023
2	Interleukin-10 (Interleukin 10)IBA 01/2022 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 09/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2019
2	Interleukin-2 (IL2)IBA 01/2021 - 03/2016
2	LigandsIBA 03/2020 - 01/2018
2	CateninsIBA 01/2019 - 12/2014
2	GTP Phosphohydrolases (GTPases)IBA 01/2016 - 10/2013
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 05/2024
1	A-Form DNA (A-DNA)IBA 03/2024
1	Immunoglobulins (Immunoglobulin)IBA 01/2024
1	Immune Checkpoint ProteinsIBA 01/2024
1	Interleukin-15 (Interleukin 15)IBA 01/2024
1	Tyrosine (L-Tyrosine)FDA Link 01/2024
1	Bevacizumab (Avastin)FDA Link 01/2024
1	PlatinumIBA 12/2023
1	CD7 AntigensIBA 11/2023
1	EP4 Subtype Prostaglandin E ReceptorsIBA 10/2023
1	Phosphotransferases (Kinase)IBA 10/2023
1	Bispecific AntibodiesIBA 07/2023
1	B7-H1 AntigenIBA 01/2023
1	Thomsen-Friedenreich antibodiesIBA 01/2023
1	parecoxibIBA 01/2023
1	Tramadol (K315)FDA LinkGeneric 01/2023
1	Fentanyl (Sublimaze)FDA LinkGeneric 01/2023
1	flurbiprofen axetilIBA 01/2023
1	MTOR InhibitorsIBA 01/2023
1	Circular RNAIBA 12/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2022
1	cabozantinibIBA 08/2021
1	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021
1	Interleukin-10 ReceptorsIBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	polyethylene glycol-poly(lactide-co-glycolide)IBA 02/2020
1	SirtuinsIBA 01/2020
1	Superoxides (Superoxide)IBA 01/2020
1	Daunorubicin (Cerubidine)FDA LinkGeneric 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Rituximab (Mabthera)FDA Link 01/2019
1	Therapeutic UsesIBA 01/2019
1	Gefitinib (Iressa)FDA Link 01/2019
1	CollagenIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019

Therapy/Procedure

11	Therapeutics 05/2024 - 05/2018
7	Immunotherapy 04/2024 - 01/2019
5	Drug Therapy (Chemotherapy) 01/2023 - 10/2013
2	Transplantation 11/2018 - 05/2014
1	Hematopoietic Stem Cell Transplantation 10/2023
1	Kidney Transplantation 01/2023